Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ ...

The partnership is supported by the Michael J. Fox Foundation, which seeks to better understand aSyn protein's role in Parkinson's disease.

Data provide validation of the Vaxxinity (VAXX) platform’s ability to selectively target aggregated, toxic forms of neurodegenerative proteins UB-312 is designed to target aggregated forms of aSyn, ...

Data from the Syn-Sleep Study shows the Syn-One Test detected phosphorylated alpha-synuclein in skin biopsies of 75% of patients with iRBD at baseline This NIH-sponsored, multicenter, prospective ...

The MarketWatch News Department was not involved in the creation of this content. SynuSight Biotech has licensed (18) F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein ...

"This grant from MJFF will accelerate our efforts to quantify and monitor alpha-synuclein progression over time," said Todd Levine, MD, Chief Medical Officer, CND Life Sciences. "We are optimistic ...

Amsterdam, July 22, 2024 – To date Parkinson's disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker ...

In studies with genetically engineered mice, Johns Hopkins Medicine researchers say they have identified a potentially new biological target involving Aplp1, a cell surface protein that drives the ...

“These are the first data to link ASC speck assembly, NLRP1 inflammasome activation, and alpha-synuclein aggregation in neurons of Parkinson’s disease patients,” said Stephen C. Glover, ZyVersa’s ...

SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. 05, 2026 (GLOBE NEWSWIRE) -- SynuSight Biotech (“SynuSight”), a biotechnology company dedicated to the development of diagnostic solutions for ...